Arcus Biosciences, Inc. Financials

Market Capitalization $1.20 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-3.17
Forward PE	-2.82
Price to Sales TTM	$4.58
Price to Book MRQ	$2.13
Enterprise to Revenue	0.74
Enterprise to EBITDA	-0.68

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-102.66%
Operating Margin	-218.75%
Return on Assets TTM	-15.25%
Return on Equity TTM	-49.77%

Income Statement

Revenue TTM	$263,000,000
Revenue per Share TTM	$3.06
Quarterly Revenue Growth	50.00%
Gross Profit TTM	$-177,000,000
EBITDA	$-288,000,000
Net Income to Common TTM	$-270,000,000
Diluted EPS TTM	$-3.19
Quarterly Earnings Growth YoY	50.00%

Balance Sheet

Total Cash MRQ	$1,088,999,936
Total Cash per Share MRQ	$11.90
Total Debt MRQ	$
Total Debt to Equity MRQ	13.98
Current Ratio MRQ	5.24
Book Value per Share MRQ	$6.18

Cash Flow

Operating Cash Flow TTM	$-158,000,000
Levered Free Cash Flow TTM	$-53,500,000

RCUS Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	91,511,600
Float Shares	51,478,025
Avg 10 Volume	701,170
Avg 30 Volume	None
Shares Short	7,751,443
Short Ratio	11.22
Short % of Shares	17.47%
% Held by Insiders	38.88%
% Held by Institutions	59.66%

Stock Price Summary

Beta	0.89
Fifty Two Week Low	$12.88
Fifty Two Week High	$20.31
Fifty Two Week Change	-16.26%
Day 50 MA	$15.43
Day 200 MA	$15.90

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date